REBOOT #226 Kidney Boy on Acute Kidney Injury: Myths & Musings
The Curbsiders Internal Medicine Podcast
Hope in Numbers: New Agents Show Promise Against NSF
Recent advancements in gadolinium-based contrast agents have led to a significant reassessment of their safety in patients with chronic kidney disease (CKD). Historically, there were considerable concerns about the risk of nephrogenic systemic fibrosis (NSF) associated with these agents, particularly in patients with stage IV or V CKD. However, a pivotal meta-analysis involving nearly 5,000 patients with CKD, including those on dialysis, revealed no cases of NSF among recipients of newer gadolinium agents. This finding offers strong reassurance regarding the safety of these agents in non-dialysis patients. While there remains cautious consideration for those on dialysis, the data indicates a promising shift in the understanding of the risks involved with the newer gadolinium agents, suggesting a potential for safer imaging practices in CKD patients.
Remember Everything You Learn from Podcasts
